SCHEMBL5022892

SCHEMBL5022892

Nc1cc(Cl)nc(-c2cccnc2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.51
ADORA2B P29275 4/20 0.51
NQO2 P16083 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.48
ALDH1A1 P00352 2/20 0.48
MAPT P10636 2/20 0.48
TP53 P04637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
HTT P42858 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TSHR P16473 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CYP2A6 P11509 5/20 0.47
MEN1 O00255 1/20 0.46
PSIP1 O75475 1/20 0.46
AXL P30530 1/20 0.46
MKNK1 Q9BUB5 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4631802 0.88 SMN1; SMN2 (0.57) SMN1; SMN2ALDH1A1MAPTTP53KDM4E
SCHEMBL30579341 0.88 SMN1; SMN2 (0.57) SMN1; SMN2ALDH1A1MAPTTP53KDM4E
SCHEMBL19830922 0.83 ADORA2A (0.59) ADORA2AADORA2BNQO2SMN1; SMN2ALDH1A1
SCHEMBL13868443 0.81 NQO2 (0.52) ADORA2AADORA2BNQO2ALDH1A1MAPT
SCHEMBL3156245 0.80 ADORA2A (0.66) ADORA2AADORA2BSMN1; SMN2ALDH1A1MAPT
SCHEMBL4631312 0.80 LMNA (0.67) SMN1; SMN2ALDH1A1MAPTTP53KDM4E
SCHEMBL19054158 0.80 ADORA2A (0.71) ADORA2AADORA2BNQO2SMN1; SMN2ALDH1A1
SCHEMBL5672174 0.79 HTT (0.46) ADORA2AADORA2BNQO2SMN1; SMN2MAPT
SCHEMBL25458352 0.78 CYP19A1 (0.51) SMN1; SMN2ALDH1A1MAPTTP53KDM4E
SCHEMBL5483622 0.78 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1MAPTTP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
CN-1953975-A 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists ALMIRALL PRODESFARMA AG (CH) 2007-04-25 CN disclosed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA2B 4/4885NQO2 1376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.